Last reviewed · How we verify
SMOFlipid + Omegaven
SMOFlipid + Omegaven is a lipid emulsion combination that provides essential fatty acids and nutritional support for parenteral nutrition, with Omegaven supplying omega-3 fatty acids to modulate inflammatory responses.
SMOFlipid + Omegaven is a lipid emulsion combination that provides essential fatty acids and nutritional support for parenteral nutrition, with Omegaven supplying omega-3 fatty acids to modulate inflammatory responses. Used for Parenteral nutrition support in critically ill patients, Post-operative nutritional support, Patients unable to tolerate enteral nutrition.
At a glance
| Generic name | SMOFlipid + Omegaven |
|---|---|
| Also known as | SMOFlipid 20% Fresenius Kabi + Omegaven 10% Fresenius Kabi |
| Sponsor | General University Hospital, Prague |
| Drug class | Lipid emulsion / Parenteral nutrition supplement |
| Modality | Small molecule |
| Therapeutic area | Critical Care / Nutritional Support |
| Phase | FDA-approved |
Mechanism of action
SMOFlipid is a structured lipid emulsion containing soybean oil, medium-chain triglycerides, olive oil, and fish oil, designed to provide balanced essential fatty acids for parenteral nutrition. Omegaven is a pure fish oil (omega-3) emulsion that provides additional anti-inflammatory omega-3 polyunsaturated fatty acids. Together, they support metabolic needs while potentially reducing inflammatory complications in critically ill or post-operative patients requiring intravenous nutrition.
Approved indications
- Parenteral nutrition support in critically ill patients
- Post-operative nutritional support
- Patients unable to tolerate enteral nutrition
Common side effects
- Hypertriglyceridemia
- Infusion-related reactions
- Hepatic steatosis
- Thrombophlebitis at infusion site
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SMOFlipid + Omegaven CI brief — competitive landscape report
- SMOFlipid + Omegaven updates RSS · CI watch RSS
- General University Hospital, Prague portfolio CI